Navigation Links
BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
Date:3/16/2010

HepaSphere™ doxorubicin delivery embolotherapy microspheres are effective in treating liver cancer, hepatocellular cancer (HCC). BioSphere Medical’s microspheres for drug delivery transarterial chemoembolization (TACE) were the subject of a clinical study presentation at the Society of Interventional Radiology (SIR) annual meeting.

(PRWEB) March 16, 2010 -- BioSphere Medical, Inc. (NASDAQ: BSMD), announced that its doxorubicin delivery embolotherapy microspheres HepaSphere™ were featured in a scientific session on the advances in minimally invasive treatments for liver cancer, at the Society of Interventional Radiology (SIR) 35th Annual Meeting, in Tampa, FL. Opening the session on transarterial chemoembolization (TACE) for liver cancer, Geert Maleux, M.D., Ph.D., an interventional radiologist at the University Hospitals Leuven, Belgium, presented the results of the first prospective, randomized clinical study demonstrating the effectiveness of HepaSphere™ to treat patients with hepatocellular cancer (HCC), the most common form of liver cancer.

Dr. Maleux’s study, conducted in Belgium, demonstrated the safety of HepaSphere™ drug delivery chemoembolization (hqTACE). Patients treated with HepaSphere™, compared to patients who received conventional transarterial chemoembolization (cTACE), had lower circulating levels of doxorubicin, which significantly reduced drug toxicity and serious side effects. The hqTACE patients also had better preserved liver function.

Today’s presentation spotlights the significant advances achieved by the company in liver cancer treatment. BioSphere has submitted an Investigational Device Exemption (IDE) application to the U.S. FDA for QuadraSphere® Microspheres for a phase III clinical trial. If approved, it will be the first phase III clinical trial for chemoembolization of primary liver cancer in the United States.    

HepaSphere™ Microspheres, however, have been CE marked in the European Union since 2007 for embolization of liver cancer and hepatic metastases, with or without delivery of doxorubicin. In the United States, QuadraSphere® is cleared by the FDA for embolization of hypervascularized tumors and peripheral arteriovenous malformations.

Surgical removal is not possible for more than two-thirds of primary liver cancer patients and 90 percent of patients with secondary liver cancer. According to the U.S. National Cancer Institute (NCI), no standard treatment currently exists for liver cancer when tumors cannot be surgically removed and liver transplantation is not a viable option.

In a related presentation, Diane K. Reyes, Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, presented results of a Phase II two-year, single-arm clinical study that treated patients with unresectable liver cancer with bevacizumab (Avastin®) and conventional TACE (cTACE) using Embosphere® Microspheres. This pilot study evaluated tumor response and safety of liver chemoembolization combined with an antiangiogenic drug that works by preventing new blood vessel growth. The data showed treatment was well tolerated, with progression-free survival of 16 months.

BioSphere Medical, Inc. (NASDAQ:BSMD) is a medical device company that develops and manufactures bioengineered microspheres for use in embolotherapy, which is the minimally invasive treatment of tumors and vascular malformations by inhibiting blood flow. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with properties that may be beneficial in a variety of medical applications. Most notably, the company was a pioneer in uterine fibroid embolization (UFE) when it launched the first approved embolic microsphere for UFE. The Company has a dominant worldwide position in UFE embolics and has developed microspheres for use in interventional oncology. BioSphere is expanding its clinical research on the use of its microspheres in liver cancer chemoembolization and other disease states. For more information, consult the company’s website at http://www.biospheremed.com/index.cfm

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company’s planned HepaSphere™/QuadraSphere® in Liver Cancer Treatment clinical trial, the expected benefits of HepaSphere and QuadraSphere for the treatment of liver cancer, and the effectiveness of HepaSphere™/QuadraSphere® to deliver the chemotherapeutic drug doxorubicin in patients with hepatocellular cancer; and treatment benefits of Embosphere® and bevacizumab in liver cancer. The Company may use words such as "plans," "seeks," "projects," "believes," "may," "anticipates," "estimates," "should," "intends," "looking forward," and similar expressions to identify these forward-looking statements. These statements are subject to risks and uncertainties and are based upon the Company's beliefs and assumptions. There are a number of important factors that may affect the Company's actual performance and results and the accuracy of its forward-looking statements, many of which are beyond the Company's control and are difficult to predict. These and other risk factors are discussed under “Risk Factors” and elsewhere in BioSphere Medical, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2008, in its Quarterly Report on Form 10-Q for the quarter ended December 31, 2009 and other filings that the Company makes from time to time with the U.S. Securities and Exchange Commission (SEC). BioSphere Medical, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

###

Read the full story at http://www.prweb.com/releases/livercancerembolization/SIR/prweb3465204.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
2. Renowned Medical Tourism Industry Expert and Author Josef D. Woodman Joins Satori World Medical's Strategic Advisory Board
3. Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board
4. Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee
5. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
6. Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres
7. Scientific Paper Supports Micro-Bland Embolization Technique for Liver Cancer With Embozene(TM) Microspheres
8. Safe Crossing Week 2007 Teaches Kids How to Behave Safely Around Trains
9. Federal Regulation Will Require Renovators to Work Safely with Lead-Paint
10. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
11. Allergic-like reactions to iodinated contrast material treated safely with commonly used medications
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a path to ... society can control and change. , As nearly 795,000 Americans suffering from a new ... United States. Plus, with an estimated 129,000 of these people dying from stroke, it’s ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, courtesy of leaders in the nursing and ... within the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... outcomes, hosted members and suppliers for its inaugural Member Conference at the Paris ... mission of elevating the operational health of America’s healthcare providers. , The conference ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John ... a new model of care for living and healing, celebrated its grand opening, today. ... in a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25, 2016 According to market ... Growth and Demand Forecast to 2022 - Industry Insights ... Others)" published by P&S Market Research, the global insulin ... 2015, and it is expected to grow at a ... insulin pump segment is expected to witness the fastest ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
Breaking Medicine Technology: